In the tumors injected with IFNγ and a galectin antagonist, CXCL9 was highly expressed in a large number of tumor sections, producing a gradient that spread up to 5.0 mm from the injection site (Fig. 5b; Supplementary Fig. 6afor individual tumors). The gene discussed is CXCL9; the disease is neoplasm.